Biotech | January 12, 2026
Complement Therapeutics’ gene therapy gains FDA fast-track for vision loss treatment
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
Vabysmo is the only injectable eye medicine approved simultaneously in the US for wet AMD and DME, with flexible dosing regimens based on patient need
It promises fewer injections for vision loss patients
Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally
ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
Subscribe To Our Newsletter & Stay Updated
